The Effects of Naloxone on Methylphenidate-induced Mood and Behavioral Changes: a Negative Study

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1980 Feb 1

PMID 6768088

Citations 1

Authors

L Y Huey

D S Janowsky

L L Judd

N A Roitman

P L Clopton

D Segal

L Hall

D Parker

Affiliations

Soon will be listed here.

Abstract

The effects of naloxone on IV methylphenidate-induced mood, behavior, and neurohumoral changes were assessed in eight psychiatric inpatients. While methylphenidate alone produced anticipated changes, the indications for significant naloxone-methylphenidate interactions were minimal. It is speculated that larger doses of naloxone might be required to produce modification of the psychostimulant effects.

Citing Articles

Influence of naloxone upon motor activity induced by psychomotor stimulant drugs.

Jones D, Holtzman S Psychopharmacology (Berl). 1994; 114(2):215-24.

PMID: 7838910 DOI: 10.1007/BF02244839.

References

Holtzman S . Behavioral effects of separate and combined administration of naloxone and d-amphetamine. J Pharmacol Exp Ther. 1974; 189(1):51-60. View

Terenius L, Wahlstrom A, Lindstrom L, Widerlov E . Increased CSF levels of endorphines in chronic psychosis. Neurosci Lett. 2009; 3(3):157-62. DOI: 10.1016/0304-3940(76)90086-0. View

Janowsky D, Leichner P, Parker D, Judd L, Huey L, Clopton P . The effect of methylphenidate on serum growth hormone: influence of antipsychotic drugs and diagnosis. Arch Gen Psychiatry. 1978; 35(11):1384-9. DOI: 10.1001/archpsyc.1978.01770350110011. View

Davis G, Bunney Jr W, DeFraites E, Kleinman J, VAN KAMMEN D, Post R . Intravenous naloxone administration in schizophrenia and affective illness. Science. 1977; 197(4298):74-7. DOI: 10.1126/science.325650. View

Volavka J, Mallya A, Baig S, PEREZ-CRUET J . Naloxone in chronic schizophrenia. Science. 1977; 196(4295):1227-8. DOI: 10.1126/science.860138. View

Hollt V, Herz A . In vivo receptor occupation by opiates and correlation to the pharmacological effect. Fed Proc. 1978; 37(2):158-61. View

Gold M, Redmond Jr D, Donabedian R . Prolactin secretion, a measurable central effect of opiate-receptor antagonists. Lancet. 1978; 1(8059):323-4. DOI: 10.1016/s0140-6736(78)90089-2. View

Janowsky D, Davis J, Sekerke H . Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch Gen Psychiatry. 1973; 28(2):185-91. DOI: 10.1001/archpsyc.1973.01750320023004. View

Shaar C, Frederickson R, Dininger N, Jackson L . Enkephalin analogues and naloxone modulate the release of growth hormone and prolactin--evidence for regulation by an endogenous opioid peptide in brain. Life Sci. 1977; 21(6):853-60. DOI: 10.1016/0024-3205(77)90415-5. View

10.

Parker D, Rossman L, Vander Laan E . Sleep-related, nychthermeral and briefly episodic variation in human plasma prolactin concentrations. J Clin Endocrinol Metab. 1973; 36(6):1119-24. DOI: 10.1210/jcem-36-6-1119. View

11.

Judd L, Hubbard R, Huey L, Attewell P, Janowsky D, Takahashi K . Lithium carbonate and ethanol induced "highs" in normal subjects. Arch Gen Psychiatry. 1977; 34(4):463-7. DOI: 10.1001/archpsyc.1977.01770160097008. View

12.

Green R, Bigelow L, OBrien P, Stahl D, Wyatt R . The Inpatient Behavioral Rating Scale: a 26-item scale for recording nursing observations of patients' mood and behavior. Psychol Rep. 1977; 40(2):543-9. DOI: 10.2466/pr0.1977.40.2.543. View

13.

VAN KAMMEN D, Murphy D . Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment. Psychopharmacologia. 1975; 44(3):215-24. DOI: 10.1007/BF00428897. View

14.

Gunne L, Lindstrom L, Terenius L . Naloxone-induced reversal of schizophrenic hallucinations. J Neural Transm. 1977; 40(1):13-9. DOI: 10.1007/BF01250276. View

15.

Belluzzi J, Stein L . Enkephalin may mediate euphoria and drive-reduction reward. Nature. 1977; 266(5602):556-8. DOI: 10.1038/266556a0. View

16.

Byck R . Peptide transmitters: a unifying hypothesis for euphoria, respiration, sleep, and the action of lithium. Lancet. 1976; 2(7976):72-3. DOI: 10.1016/s0140-6736(76)92289-3. View

17.

Janowsky D, Judd L, Huey L, Roitman N, Parker D, Segal D . Naloxone effects on manic symptoms and growth-hormone levels. Lancet. 1978; 2(8084):320. DOI: 10.1016/s0140-6736(78)91725-7. View

18.

Emrich H, Cording C, Piree S, Kolling A, von Zerssen D, Herz A . Indication of an antipsychotic action of the opiate antagonist naloxone. Pharmakopsychiatr Neuropsychopharmakol. 1977; 10(5):265-70. DOI: 10.1055/s-0028-1094547. View

19.

Bruni J, van Vugt D, Marshall S, Meites J . Effects of naloxone, morphine and methionine enkephalin on serum prolactin, luteinizing hormone, follicle stimulating hormone, thyroid stimulating hormone and growth hormone. Life Sci. 1977; 21(3):461-6. DOI: 10.1016/0024-3205(77)90528-8. View

20.

Janowsky D, Huey L, Storms L, Judd L . Methylphenidate hydrochloride effects on psychological tests in acute schizophrenic and nonpsychotic patients. Arch Gen Psychiatry. 1977; 34(2):189-94. DOI: 10.1001/archpsyc.1977.01770140079009. View